TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF THE EUROPE BLADDER CANCER DIAGNOSTICS MARKET 26
1.4 CURRENCY AND PRICING 27
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.6 MULTIVARIATE MODELLING 37
2.7 TEST TYPE SEGMENT LIFELINE CURVE 37
2.8 MARKET END USER COVERAGE GRID 38
2.9 DBMR MARKET POSITION GRID 39
2.10 VENDOR SHARE ANALYSIS 40
2.11 SECONDARY SOURCES 41
2.12 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 44
4.1 PESTLE ANALYSIS 45
4.2 PORTER'S FIVE FORCES MODEL 46
5 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT 47
6 REGULATORY FRAMEWORK 49
7 MARKET OVERVIEW 50
7.1 DRIVERS 52
7.1.1 RISING INCIDENCE OF BLADDER CANCER EUROPELY 52
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER 52
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY 53
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS 53
7.2 RESTRAINTS 54
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER 54
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES 54
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS 54
7.3 OPPORTUNITIES 55
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER 55
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS 55
7.3.3 INCREASE IN THE GERIATRIC POPULATION 56
7.4 CHALLENGES 56
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING 56
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES 57
8 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 58
8.1 OVERVIEW 59
8.2 CYSTOSCOPY 62
8.3 URINE LAB TEST 62
8.3.1 URINE CYTOLOGY 64
8.3.2 URINALYSIS 64
8.3.3 URINE TUMOR MARKER TEST 64
8.3.4 URINE CULTURE 64
8.3.5 OTHERS 64
8.4 BIOPSY 64
8.5 IMAGING TEST 65
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 66
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN 66
8.5.3 ULTRASOUND 66
8.5.4 INTRAVENOUS PYELOGRAM (IVP) 67
8.6 OTHERS 67
9 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES 68
9.1 OVERVIEW 69
9.2 STAGE IV 72
9.3 STAGE III 72
9.4 STAGE II 73
9.5 STAGE I 74
10 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 76
10.1 OVERVIEW 77
10.2 TRANSITIONAL CELL BLADDER CANCER 80
10.3 SQUAMOUS CELL BLADDER CANCER 81
10.4 OTHER CANCER TYPES 82
11 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY END USER 83
11.1 OVERVIEW 84
11.2 HOSPITAL 87
11.3 DIAGNOSTIC IMAGING CENTERS 87
11.4 CANCER RESEARCH INSTITUTES 88
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES 89
11.6 ASSOCIATED LABS 90
12 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 91
12.1 OVERVIEW 92
12.2 DIRECT TENDER 95
12.3 RETAIL SALES 95
13 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY REGION 97
13.1 EUROPE 98
13.1.1 GERMANY 105
13.1.2 FRANCE 107
13.1.3 U.K. 109
13.1.4 ITALY 111
13.1.5 SPAIN 113
13.1.6 RUSSIA 115
13.1.7 TURKEY 117
13.1.8 NETHERLANDS 119
13.1.9 BELGIUM 121
13.1.10 SWITZERLAND 123
13.1.11 REST OF EUROPE 125
14 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 126
14.1 COMPANY SHARE ANALYSIS: EUROPE 126
15 SWOT ANALYSIS 127
16 EUROPE BLADDER CANCER DIAGNOSTICS MARKET 128
16.1 F. HOFFMANN- LA ROCHE LTD 128
16.1.1 COMPANY SNAPSHOT 128
16.1.2 REVENUE ANALYSIS 128
16.1.3 COMPANY SHARE ANALYSIS 129
16.1.4 PRODUCT PORTFOLIO 129
16.1.5 RECENT DEVELOPMENTS 129
16.2 MERCK KGAA 130
16.2.1 COMPANY SNAPSHOT 130
16.2.2 REVENUE ANALYSIS 130
16.2.3 COMPANY SHARE ANALYSIS 131
16.2.4 PRODUCT PORTFOLIO 131
16.2.5 RECENT DEVELOPMENT 131
16.3 THERMO FISHER SCIENTIFIC INC. 132
16.3.1 COMPANY SNAPSHOT 132
16.3.2 REVENUE ANALYSIS 132
16.3.3 COMPANY SHARE ANALYSIS 133
16.3.4 PRODUCT PORTFOLIO 133
16.3.5 RECENT DEVELOPMENT 133
16.4 KONINLIJKE PHILIPS N.V. 134
16.4.1 COMPANY SNAPSHOT 134
16.4.2 REVENUE ANALYSIS 134
16.4.3 COMPANY SHARE ANALYSIS 135
16.4.4 PRODUCT PORTFOLIO 135
16.4.5 RECENT DEVELOPMENT 135
16.5 BIO-RAD LABORATORIES, INC. 136
16.5.1 COMPANY SNAPSHOT 136
16.5.2 COMPANY SNAPSHOT 136
16.5.3 COMPANY SHARE ANALYSIS 137
16.5.4 PRODUCT PORTFOLIO 137
16.5.5 RECENT DEVELOPMENT 137
16.6 ABBOTT 138
16.6.1 COMPANY SNAPSHOT 138
16.6.2 REVENUE ANALYSIS 138
16.6.3 PRODUCT PORTFOLIO 139
16.6.4 RECENT DEVELOPMENT 139
16.7 AGILENT TECHNOLOGIES, INC. 140
16.7.1 COMPANY SNAPSHOT 140
16.7.2 REVENUE ANALYSIS 140
16.7.3 PRODUCT PORTFOLIO 141
16.7.4 RECENT DEVELOPMENT 141
16.8 AMBU A/S 142
16.8.1 COMPANY SNAPSHOT 142
16.8.2 REVENUE ANALYSIS 142
16.8.3 PRODUCT PORTFOLIO 143
16.8.4 RECENT DEVELOPMENT 143
16.9 BD 144
16.9.1 COMPANY SNAPSHOT 144
16.9.2 REVENUE ANALYSIS 144
16.9.3 PRODUCT PORTFOLIO 145
16.9.4 RECENT DEVELOPMENT 145
16.10 CANON MEDICAL SYSTEMS CORPORATION 146
16.10.1 COMPANY SNAPSHOT 146
16.10.2 REVENUE ANALYSIS 146
16.10.3 PRODUCT PORTFOLIO 147
16.10.4 RECENT DEVELOPMENT 147
16.11 CEPHEID 148
16.11.1 COMPANY SNAPSHOT 148
16.11.2 REVENUE ANALYSIS 148
16.11.3 PRODUCT PORTFOLIO 149
16.11.4 RECENT DEVELOPMENTS 149
16.12 FUJIFILM CORPORATION 150
16.12.1 COMPANY SNAPSHOT 150
16.12.2 REVENUE ANALYSIS 150
16.12.3 PRODUCT PORTFOLIO 151
16.12.4 RECENT DEVELOPMENTS 151
16.13 GENERAL ELECTRIC COMPANY 152
16.13.1 COMPANY SNAPSHOT 152
16.13.2 REVENUE ANALYSIS 152
16.13.3 PRODUCT PORTFOLIO 153
16.13.4 RECENT DEVELOPMENTS 153
16.14 HOLOGIC INC. 154
16.14.1 COMPANY SNAPSHOT 154
16.14.2 REVENUE ANALYSIS 154
16.14.3 PRODUCT PORTFOLIO 155
16.14.4 RECENT DEVELOPMENT 155
16.15 ILLUMINA INC 156
16.15.1 COMPANY SNAPSHOT 156
16.15.2 REVENUE ANALYSIS 156
16.15.3 PRODUCT PORTFOLIO 157
16.15.4 RECENT DEVELOPMENTS 157
16.16 MINFOUND MEDICAL SYSTEMS CO., 158
16.16.1 COMPANY SNAPSHOT 158
16.16.2 PRODUCT PORTFOLIO 158
16.16.3 RECENT DEVELOPMENTS 158
16.17 NEUSOFT CORPORATION 159
16.17.1 COMPANY SNAPSHOT 159
16.17.2 COMPANY SNAPSHOT 159
16.17.3 PRODUCT PORTFOLIO 160
16.17.4 RECENT DEVELOPMENT 160
16.18 QIAGEN 161
16.18.1 COMPANY SNAPSHOT 161
16.18.2 REVENUE ANALYSIS 161
16.18.3 PRODUCT PORTFOLIO 162
16.18.4 RECENT DEVELOPMENT 162
16.19 SIEMENS HEALTHCARE GMBH 163
16.19.1 COMPANY SNAPSHOT 163
16.19.2 REVENUE ANALYSIS 163
16.19.3 PRODUCT PORTFOLIO 164
16.19.4 RECENT DEVELOPMENT 165
16.20 TIME MEDICAL HOLDING. 166
16.20.1 COMPANY SNAPSHOT 166
16.20.2 PRODUCT PORTFOLIO 166
16.20.3 RECENT DEVELOPMENTS 166
17 QUESTIONNAIRE 167
18 RELATED REPORTS 170

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.